Is Sat Kartar overvalued or undervalued?

As of 6 October 2025, the valuation grade for Sat Kartar has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 23.25, an EV to EBITDA of 14.30, and a ROCE of 48.39%.
In comparison to its peers, Sat Kartar's valuation stands out; for instance, Sun Pharma has a PE Ratio of 34.56 and an EV to EBITDA of 23.42, while Cipla is valued attractively with a PE of 22.72 and an EV to EBITDA of 15.97. Despite recent stock performance showing a decline of 2.75% over the past week against a Sensex increase of 1.80%, the overall valuation metrics suggest that Sat Kartar presents a compelling investment opportunity in the pharmaceuticals and biotechnology sector.